alexa
Reach Us +1(850)754-6199
Nano Vaccines For Infectious Diseases | 17072
ISSN: 2155-952X

Journal of Biotechnology & Biomaterials
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Nano vaccines for infectious diseases

5th World Congress on Biotechnology

Martin J D?Souza

ScientificTracks Abstracts: J Biotechnol Biomater

DOI: 10.4172/2155-952X.S1.027

Abstract
Recent years have seen the development of novel technologies using nanoparticles and microparticles to deliver vaccines by the oral and transdermal route of administration. These new technologies enable the formulation of vaccine particles containing vaccine antigens, without loss of their biological activity during the formulation process. Also, multiple antigens, targeting ligands and adjuvants can all be encapsulated within in the same particle. When administered orally, these particles are designed to withstand the acidic environment of the stomach and are targeted to the Peyer?s patches and the gut associated mucosal immune system. Since these vaccines are particulate in nature, they are readily taken up by phagocytic antigen presenting cells (APC?s), such as M cells, dendritic cells and macrophages in the Peyer?s patches of the intestines, resulting in a strong immune response and antibody production. Of particular interest in this formulation is the fact that the particles release the antigen in a slow and sustained manner over a prolonged time period, intracellularly into APC?s, resulting in strong mucosal and systemic immunity after oral administration, without the need for added adjuvants that are typically present in current vaccine preparations. Since no needles are required, for oral vaccines, this method of vaccine delivery is inexpensive and suitable for mass vaccination in the developing world as well as for the developed world. This presentation discusses studies conducted on a wide array of vaccines including infectious disease vaccines such as TB, typhoid, influenza, pneumonia, meningitis and hepatitis B vaccine antigens suggest that this delivery system is highly suitable for antigens to be used for protective immunity. This method of vaccine delivery enables the delivery of a wide spectrum of vaccines for prophylactic and therapeutic use.
Biography
Martin J D?Souza has completed his PhD from the University of Pittsburgh, PA. He is the director of Graduate Programs at Mercer University, College of Pharmacy and Co-Director of the Center for Drug Delivery. He has published more than 80 manuscripts and is on the editorial board of several journals.
Top